COMMUNIQUÉS West-GlobeNewswire

aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate
26/06/2018
ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports Potential Once-Monthly Dosing SAN DIEGO, June 26, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE [...]
Nu-Med Plus, Inc. Selects s2s Public Relations firm as its Strategic Partner
26/06/2018
The firm specializes in driving investor interest SALT LAKE CITY, June 26, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc . (OTCQB:NUMD), a medical device company which investigates and develops nitric oxide applications of [...]
7 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program
26/06/2018
HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a privately-held immunotherapy company focused on development of novel tumor-targeting cell adhesion agents, announced today the formation of its Scientific [...]
ZEMDRITM (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)
26/06/2018
― ZEMDRI is a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae ― ― ZEMDRI is the only once-daily aminoglycoside therapy approved for use in cUTI ― ― ZEMDRI has [...]
Precipio and Nucleai Partner to Develop Artificial Intelligence-Powered Hemepath Solution
26/06/2018
System will support Hematopathologists in accurately identifying abnormalities to ensure diagnostic accuracy NEW HAVEN, Conn., June 26, 2018 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO [...]
Arch Therapeutics Provides Skin Sensitization Study Status Update
26/06/2018
Approximately two-thirds of applications in the repeat dosing induction phase are completed; Study remains on track FRAMINGHAM, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or [...]
SELLAS Life Sciences Announces Proposed Public Offering of Common Stock
26/06/2018
NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or “the Company”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range [...]
Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting
26/06/2018
Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting Leading cancer supportive care experts in oncology explore how to provide the best care for patients by discussing the importance [...]
Solon Eiendom ASA : Primary insider notification
26/06/2018
(Oslo, Norway, June 25, 2018) UFI AS has today bought 38.664 shares in Solon Eiendom ASA at a price of NOK 29.9097 per share. Solon Eiendom ASA Board Member Øystein A. Landvik owns 33,34 % of the shares in UFI AS. [...]
Shire plc : Rule 2.9 Announcement
26/06/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 26 June 2018 Shire [...]
IBT plans to start its phase 3 study in the second half of 2018 and contracts CRO
26/06/2018
IBT has previously announced its plan to start the phase 3 study in the first half of 2018. Preparations for the study have taken slightly longer than expected and the Company now plans to initiate the phase 3 study in [...]
FIT Biotech Oy: EHVA clinical trial authorization granted for testing FIT-06 in UK
26/06/2018
FIT Biotech Oy Company release 26.6.2018 at 8:30 AM EET EHVA clinical trial authorization granted for testing FIT-06 in UK FIT Biotech Oy ("Company", FITBIO: FN Finland) today announced that the UK medical authorities [...]
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
26/06/2018
Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also highlights that over 50% [...]
Basilea starts clinical phase 2a expansion with BAL101553 in ovarian cancer and glioblastoma
26/06/2018
Basel, Switzerland, June 26, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the first patient has been dosed in the phase 2a expansion part of Basilea's ongoing phase 1/2a clinical study with its [...]
Fagron NV: Disclosure of received notifications
26/06/2018
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 June 2018 - 6:30am (CET) Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron [...]
Immuron Announces Board Appointment
26/06/2018
MELBOURNE, Australia, June 25, 2018 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company Immuron Limited (ASX:IMC), is pleased to announce the appointment of New York based Mr. Richard Jay Berman to serve as a [...]
Zomedica Joins Russell 3000™ and Russell Microcap® Indexes
25/06/2018
ANN ARBOR, Mich., June 25, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic and pharmaceutical company, today announced that [...]
Wave Life Sciences to Present at Parent Project Muscular Dystrophy Annual Conference
25/06/2018
CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases [...]
UPDATE: Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
25/06/2018
ARLINGTON, Va., June 25, 2018 (GLOBE NEWSWIRE) -- Today IMV, part of the Science and Medicine Group, and the leading market research and business intelligence provider to the Imaging industry, announced the category [...]

Pages